Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akiko Ishitani is active.

Publication


Featured researches published by Akiko Ishitani.


Immunity | 1995

The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association

Ni Lee; Alison R. Malacko; Akiko Ishitani; Ming-Chu Chen; Jürgen Bajorath; Hans Marquardt; Daniel E. Geraghty

The class Ib antigen HLA-G is expressed as a membrane-bound protein like classical class Ia molecules (M.HLA-G) but, unlike typical class I, is also expressed as a soluble protein (S.HLA-G) with a unique C terminus. Our results show that, similar to classical class I proteins, the membrane-bound form of HLA-G associated with TAP, as evidenced by the ability to immunoprecipitate HLA-G class I heavy chain with TAP antisera. In contrast, the soluble G protein did not appear to associate with TAP in the same manner, since similar immunoprecipitation experiments failed to detect soluble G complex. A detailed analysis of peptides bound to the soluble and membrane HLA-G proteins expressed in the B lymphoblastoid cell line 721.221 showed that, like class Ia complexes, both HLA-G proteins consist of heavy and light chains complexed with nonameric peptides in a 1:1:1 ratio. The two proteins bind essentially the same set of peptides, which are derived from a variety of intracellular proteins and define a peptide motif for HLA-G. The peptides contain Leu at the C terminus and Pro or small hydrophobic amino acids in position 3 followed by Pro or Gly in position 4. The complexity of the bound peptides is lower than that found for some class Ia complexes, but is more similar to class Ia than to the limited repertoire of some murine class Ib molecules.


Journal of Immunology | 2003

Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F, and G in Maternal-Placental Immune Recognition

Akiko Ishitani; Noriko Sageshima; Ni Lee; Natalia Dorofeeva; Katsuhiko Hatake; Hans Marquardt; Daniel E. Geraghty

In this study we focused on the structure and expression of the HLA-E, F, and G class I complexes in placental tissue. Structural analysis included an examination of the peptides bound to soluble and membrane forms of the HLA-G complex isolated directly from placenta. An important distinction was observed from HLA-G bound peptides previously isolated from transfectant cells. Thus, the number of distinct moieties bound to placental-derived proteins was substantially lower than that bound to transfectant-derived HLA-G. Indeed, a single peptide species derived from a cytokine-related protein alone accounted for 15% of the molar ratio of HLA-G bound peptide. To further examine HLA-E and its potential to bind peptide, notably that derived from HLA-G, we combined new Abs to examine expression in placental tissues for all the known forms of the nonclassical class I molecules. Whereas membrane HLA-G was found in extravillous trophoblasts, soluble HLA-G was found in all placental trophoblasts, including villous cytotrophoblasts and syncitiotrophoblasts. Further, HLA-E was found in all cells that expressed either form of HLA-G, consistent with HLA-E being complexed with the HLA-G signal sequence-derived nonamer in these cells. Finally, using new reagents specific for HLA-F, a restricted pattern of expression was observed, primarily on extravillous trophoblasts that had invaded the maternal decidua. Comparative staining indicated that HLA-F was on the surface of these cells, defining them as the first to demonstrate surface expression of this Ag and the first cell type identified to express all three nonclassical HLA class I Ags simultaneously.


European Journal of Immunology | 2010

HLA‐F is a surface marker on activated lymphocytes

Ni Lee; Akiko Ishitani; Daniel E. Geraghty

Of the three nonclassical class I antigens expressed in humans, HLA‐F has been least characterized with regard to expression or function. In this study, we examined HLA‐F expression focusing on lymphoid cells, where our previous work with homologous cell lines had demonstrated surface HLA‐F expression. HLA‐F protein expression was observed by Western blot analysis in all resting lymphocytes, including B cells, T cells, NK cells, and monocytes, all of which lacked surface expression in the resting state. Upon activation, using a variety of methods to activate different lymphocyte subpopulations, all cell types that expressed HLA‐F intracellularly showed an induction of surface HLA‐F protein. An examination of peripheral blood from individuals genetically deficient for TAP and tapasin expression demonstrated the same activation expression profiles for HLA‐F, but with altered kinetics post‐activation. Further analysis of CD4+CD25+ Treg showed that HLA‐F was not upregulated on the major fraction of these cells when they were activated, whereas CD4+CD25− T cells showed strong expression of surface HLA‐F when activated under identical conditions. These findings are discussed with regard to possible functions for HLA‐F and its potential clinical use as a marker of an activated immune response.


Immunological Reviews | 2002

Genetics of the immune response: identifying immune variation within the MHC and throughout the genome.

Daniel E. Geraghty; Riza Daza; Luke M. Williams; Quyen Vu; Akiko Ishitani

Summary: With the advent of modern genomic sequencing technology the ability to obtain new sequence data and to acquire allelic polymorphism data from a broad range of samples has become routine. In this regard, our investigations have started with the most polymorphic of genetic regions fundamental to the immune response in the major histocompatibility complex (MHC). Starting with the completed human MHC genomic sequence, we have developed a resource of methods and information that provide ready access to a large portion of human and nonhuman primate MHCs. This resource consists of a set of primer pairs or amplicons that can be used to isolate about 15% of the 4.0 Mb MHC. Essentially similar studies are now being carried out on a set of immune response loci to broaden the usefulness of the data and tools developed. A panel of 100 genes involved in the immune response have been targeted for single nucleotide polymorphism (SNP) discovery efforts that will analyze 120 Mb of sequence data for the presence of immune‐related SNPs. The SNP data provided from the MHC and from the immune response panel has been adapted for use in studies of evolution, MHC disease associations, and clinical transplantation.


British Journal of Haematology | 2000

Aberrant expression of HLA-G antigen in interferon γ-stimulated acute myelogenous leukaemia

Shin-ichi Mizuno; Nobuhiko Emi; Masanobu Kasai; Akiko Ishitani; Hidehiko Saito

We have analysed the expression of HLA‐G in 40 leukaemia samples of various subtypes [seven cases of acute lymphoblastic leukaemia (ALL), 28 cases of acute myelogenous leukaemia (AML), three cases of chronic myelogenous leukaemia (CML) and two cases of chronic lymphocytic leukaemia (CLL)] by flow cytometry using HLA‐G‐specific monoclonal antibody. No leukaemia samples expressed HLA‐G without incubation with interferon (IFN)‐γ. However, six out of 28 (21%) AML samples expressed HLA‐G upon incubation with IFN‐γ. These six samples derived from one out of seven M2, two out of eight M4 and three out of five M5. The results indicated that AML cells, especially myelomonocytic leukaemia samples, are capable of expressing the HLA‐G molecule.


PLOS ONE | 2016

HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1

Aura Burian; Kevin L. Wang; Kathryn A. K. Finton; Ni Lee; Akiko Ishitani; Roland K. Strong; Daniel E. Geraghty

Based on previous findings supporting HLA-F as a ligand for KIR3DL2 and KIR2DS4, we investigated the potential for MHC-I open conformers (OCs) as ligands for KIR3DS1 and KIR3DL1 through interactions measured by surface plasmon resonance. These measurements showed physical binding of KIR3DS1 but not KIR3DL1 with HLA-F and other MHC-I OC while also confirming the allotype specific binding of KIR3DL1 with MHC-I peptide complex. Concordant results were obtained with biochemical pull-down from cell lines and biochemical heterodimerization experiments with recombinant proteins. In addition, surface binding of HLA-F and KIR3DS1 to native and activated NK and T cells was coincident with specific expression of the putative ligand or receptor. A functional response of KIR3DS1 was indicated by increased granule exocytosis in activated cells incubated with HLA-F bound to surfaces. The data extend a model for interaction between MHC-I open conformers and activating KIR receptors expressed during an inflammatory response, potentially contributing to communication between the innate and adaptive immune response.


Human Immunology | 2008

Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients

Shigehiro Tamaki; Nobuyuki Sanefuzi; Masayoshi Kawakami; Kumiko Aoki; Yuichiro Imai; Yasutsugu Yamanaka; Kazuhiko Yamamoto; Akiko Ishitani; Katsuhiko Hatake; Tadaaki Kirita

The soluble form of major histocompatibility complex class I-related chain A (MICA) is released from the surface of tumor cells of epithelial origin. Although MICA expressed on the cell surface stimulates the immunoreceptor natural killer (NK) group 2, member D (NKG2D), the secreted form downregulates NKG2D activity, thus allowing the tumor to escape immunosurveillance by NKG2D-expressing cells. In this study, we examined the association between serum levels of soluble MICA and the severity of disease in patients with oral squamous cell carcinoma (OSCC). We used enzyme-linked immunoabsorbent assay to measure serum levels of soluble MICA in OSCC patients and normal control individuals. Among patients categorized according to most disease parameters tested (tumor size, location, grade of differentiation, regional lymph node status, disease stage), soluble MICA levels in sera did not statistically differ from those in normal control individuals. Patients with stage IV disease and/or regional lymph node metastasis did, however, exhibit significantly higher serum levels of soluble MICA than control individuals (95% confidence interval (CI), 0.65-2.45, p = 0.021, and 95% CI, 0.62-4.42, p = 0.031, respectively). Overall survival rates were significantly higher for OSCC patients with low soluble MICA levels (<50 pg/ml) than for those with high soluble MICA levels (>50 pg/ml) (95% CI, 0.43-2.75, p = 0.03). Serum levels of soluble MICA may be useful in the diagnosis of advanced stage OSCC and as an indicator of regional lymph node metastasis.


Clinical Immunology | 2009

Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma.

Shigehiro Tamaki; Masayoshi Kawakami; Yasutsugu Yamanaka; Hiroyuki Shimomura; Yuichiro Imai; Jun-ichi Ishida; Kazuhiko Yamamoto; Akiko Ishitani; Katsuhiko Hatake; Tadaaki Kirita

NK and cytotoxic T cells play an important role in the elimination of virus-infected and tumor cells through NKG2D activating receptors, which can promote the lysis of target cells by binding to the major histocompatibility complex class I-related chain A (MICA) proteins. Polymorphisms in MICA may influence its binding to the NKG2D. The soluble form of MICA is released from the surface of tumor cells of epithelial origin. Whereas MICA expressed on the cell surface stimulates the immunoreceptor natural killer group 2, member D (NKG2D), the secreted form down-regulates NKG2D activity, thus allowing the tumor to escape immunosurveillance by NKG2D-expressing cells. In this study, we examined the association between MICA gene microsatellite polymorphisms and serum levels of soluble MICA in patients with oral squamous cell carcinoma (OSCC). We found that patients with OSCC were more likely to have the A5.1 allele when compared to healthy subjects and also more likely to be homozygous for this allele (p=0.041). Patients with the homozygous A5.1 genotype had higher levels of soluble MICA (p=0.031) and a lower survival rate (p=0.026).


American Journal of Reproductive Immunology | 2003

Necrotic Feature of the Trophoblasts Lacking HLA-G Expression in Normal and Pre-eclamptic Placentas

Noriko Sageshima; Akiko Ishitani; Motoko Omura; Masayoshi Akasaki; Hideshi Umekage; Hidetaka Katabuchi; Hitoshi Okamura; Katsuhiko Hatake

PROBLEM:  Human leukocyte antigen (HLA)‐G is thought to be expressed in all placental extravillous trophoblasts (EXTs). In pre‐eclamptic placentas, a lack of HLA‐G expression on EXTs had been found, and deduced as a possible cause of pre‐eclampsia. However, a subset of EXTs lacking expression of HLA‐G can also be found in normal placenta. Therefore, we sought to compare these cells in normal and pre‐eclamptic placentas.


Journal of Forensic Research | 2014

Estimating the Time after Death on the Basis of Corneal Opacity

Wataru Kawashima; Katsuhiko Hatake; Risa Kudo; Mari Nakanishi; Shigehiro Tamaki; Shogo Kasuda; Katsuya Yuui; Akiko Ishitani

Estimation of the time after death (TAD) is an important aspect of forensic science. The cornea becomes increasingly opaque with an increase in TAD and corneal opacity is used for TAD estimation. However, previous methods are subjective, and there is a risk of human error. To establish an objective method, we propose a new method for TAD estimation. We applied RGB image analysis to the corneal color of cadavers. We then examined if there was a correlation between these color parameters and actual TAD, age, position at death, and environmental temperature. We found that corneal opacity was affected only by TAD. The method described here is objective and easy to use, and TAD can be estimated within a very short period of time, making this method particularly useful. To further increase the accuracy of TAD estimation, other quantifiable parameters could also be evaluated.

Collaboration


Dive into the Akiko Ishitani's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel E. Geraghty

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ni Lee

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Shogo Kasuda

Nara Medical University

View shared research outputs
Top Co-Authors

Avatar

Katsuya Yuui

Nara Medical University

View shared research outputs
Top Co-Authors

Avatar

Nobuaki Ito

Nara Medical University

View shared research outputs
Top Co-Authors

Avatar

Risa Kudo

King's College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge